ES2633987T3 - Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK - Google Patents
Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK Download PDFInfo
- Publication number
- ES2633987T3 ES2633987T3 ES14741757.0T ES14741757T ES2633987T3 ES 2633987 T3 ES2633987 T3 ES 2633987T3 ES 14741757 T ES14741757 T ES 14741757T ES 2633987 T3 ES2633987 T3 ES 2633987T3
- Authority
- ES
- Spain
- Prior art keywords
- carboxamide
- chromene
- pyridin
- substituted
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title 1
- 239000011435 rock Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 56
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 42
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 24
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 23
- 101150105130 RORB gene Proteins 0.000 claims abstract description 22
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 10
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims abstract description 5
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 5
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims abstract description 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- -1 (5-phenylisoxazol-3-yl) methyl Chemical group 0.000 claims description 78
- JBOYQZDFEWOILV-UHFFFAOYSA-N 5h-chromene Chemical compound O1C=CC=C2CC=CC=C21 JBOYQZDFEWOILV-UHFFFAOYSA-N 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 claims description 2
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 claims description 2
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- FPBXOMZZNSZCOX-GFCCVEGCSA-N 1-(difluoromethyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound FC(C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)N[C@H](C)C1=CC(=CC=C1)OC)F FPBXOMZZNSZCOX-GFCCVEGCSA-N 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- WNHMPCBFTMFRLC-UHFFFAOYSA-N COc1cccc(CNC(=O)c2ccc3c4ccncc4n(C)c(=O)c3c2)c1 Chemical compound COc1cccc(CNC(=O)c2ccc3c4ccncc4n(C)c(=O)c3c2)c1 WNHMPCBFTMFRLC-UHFFFAOYSA-N 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- VPIGHPBOTWERIL-GFCCVEGCSA-N 1-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=NC=CC2=C1NC1=CC(=CC=C21)C(=O)N[C@H](C)C1=CC(=CC=C1)OC VPIGHPBOTWERIL-GFCCVEGCSA-N 0.000 claims 1
- RLGISLYKJUGUSQ-UHFFFAOYSA-N 1-fluoro-N-[(3-fluorophenyl)methyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=NC=CC2=C1NC1=CC(=CC=C21)C(=O)NCC1=CC(=CC=C1)F RLGISLYKJUGUSQ-UHFFFAOYSA-N 0.000 claims 1
- FEIVZACOGJUUIJ-UHFFFAOYSA-N 1-fluoro-N-[(3-methoxyphenyl)methyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=NC=CC2=C1NC1=CC(=CC=C21)C(=O)NCC1=CC(=CC=C1)OC FEIVZACOGJUUIJ-UHFFFAOYSA-N 0.000 claims 1
- MNUNGKPVACPKMW-GFCCVEGCSA-N 3-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=CC2=C(NC3=CC(=CC=C23)C(=O)N[C@H](C)C2=CC(=CC=C2)OC)C=N1 MNUNGKPVACPKMW-GFCCVEGCSA-N 0.000 claims 1
- NNPMQSMSQMMCEP-UHFFFAOYSA-N 3-fluoro-N-[(3-fluorophenyl)methyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=CC2=C(NC3=CC(=CC=C23)C(=O)NCC2=CC(=CC=C2)F)C=N1 NNPMQSMSQMMCEP-UHFFFAOYSA-N 0.000 claims 1
- VYIBCOSBNVFEIW-UHFFFAOYSA-N 3-phenylpropanamide Chemical compound NC(=O)CCC1=CC=CC=C1 VYIBCOSBNVFEIW-UHFFFAOYSA-N 0.000 claims 1
- HSDLAOURKYHLIT-GFCCVEGCSA-N 4-fluoro-N-[(1R)-1-(3-methoxyphenyl)ethyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=CN=CC=2NC3=CC(=CC=C3C=21)C(=O)N[C@H](C)C1=CC(=CC=C1)OC HSDLAOURKYHLIT-GFCCVEGCSA-N 0.000 claims 1
- XMWAXVJTWIHADJ-UHFFFAOYSA-N 4-fluoro-N-[(3-fluorophenyl)methyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=CN=CC=2NC3=CC(=CC=C3C=21)C(=O)NCC1=CC(=CC=C1)F XMWAXVJTWIHADJ-UHFFFAOYSA-N 0.000 claims 1
- IKKBUPGYTNFXPN-UHFFFAOYSA-N 4-fluoro-N-[(3-methoxyphenyl)methyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=CN=CC=2NC3=CC(=CC=C3C=21)C(=O)NCC1=CC(=CC=C1)OC IKKBUPGYTNFXPN-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- OFQWIOILYATHSB-OAHLLOKOSA-N 5-ethyl-6-oxo-N-[(1R)-1-phenylethyl]benzo[c][1,7]naphthyridine-8-carboxamide Chemical compound C(C)N1C(C2=C(C3=CC=NC=C13)C=CC(=C2)C(=O)N[C@H](C)C1=CC=CC=C1)=O OFQWIOILYATHSB-OAHLLOKOSA-N 0.000 claims 1
- DJDDFFKEKDUPHF-OAHLLOKOSA-N 5-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]-6-oxobenzo[c][1,7]naphthyridine-8-carboxamide Chemical compound C(C)N1C(C2=C(C3=CC=NC=C13)C=CC(=C2)C(=O)N[C@H](C)C1=CC(=CC=C1)OC)=O DJDDFFKEKDUPHF-OAHLLOKOSA-N 0.000 claims 1
- FIYQDRKJJNDGOA-UHFFFAOYSA-N 5-ethyl-N-[(3-methoxyphenyl)methyl]-6-oxobenzo[c][1,7]naphthyridine-8-carboxamide Chemical compound C(C)N1C(C2=C(C3=CC=NC=C13)C=CC(=C2)C(=O)NCC1=CC(=CC=C1)OC)=O FIYQDRKJJNDGOA-UHFFFAOYSA-N 0.000 claims 1
- LQNSBMPWSVIMGD-MRXNPFEDSA-N 6-(2-methoxyethyl)-5-oxo-N-[(1R)-1-phenylethyl]benzo[c][2,7]naphthyridine-8-carboxamide Chemical compound COCCN1C(C2=CN=CC=C2C2=C1C=C(C=C2)C(=O)N[C@H](C)C1=CC=CC=C1)=O LQNSBMPWSVIMGD-MRXNPFEDSA-N 0.000 claims 1
- GTTGLYXERASJGT-MRXNPFEDSA-N 6-(2-methoxyethyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]-5-oxobenzo[c][2,7]naphthyridine-8-carboxamide Chemical compound COCCN1C(C2=CN=CC=C2C2=C1C=C(C=C2)C(=O)N[C@H](C)C1=CC(=CC=C1)OC)=O GTTGLYXERASJGT-MRXNPFEDSA-N 0.000 claims 1
- RMGUEWGQPAJGLO-CYBMUJFWSA-N 6-oxo-N-[(1R)-1-phenylethyl]-5H-benzo[c][1,7]naphthyridine-8-carboxamide Chemical compound O=C1NC2=CN=CC=C2C2=C1C=C(C=C2)C(=O)N[C@H](C)C1=CC=CC=C1 RMGUEWGQPAJGLO-CYBMUJFWSA-N 0.000 claims 1
- LJYFVHQERVRDRZ-UHFFFAOYSA-N 9-ethyl-N-(2-hydroxy-1-phenylethyl)pyrido[3,4-b]indole-7-carboxamide Chemical compound C(C)N1C2=C(C3=CC=C(C=C13)C(=O)NC(CO)C1=CC=CC=C1)C=CN=C2 LJYFVHQERVRDRZ-UHFFFAOYSA-N 0.000 claims 1
- KHDTWGHINMBUJH-OAHLLOKOSA-N 9-ethyl-N-[(1R)-1-(3-methoxyphenyl)ethyl]pyrido[3,4-b]indole-7-carboxamide Chemical compound C(C)N1C2=C(C3=CC=C(C=C13)C(=O)N[C@H](C)C1=CC(=CC=C1)OC)C=CN=C2 KHDTWGHINMBUJH-OAHLLOKOSA-N 0.000 claims 1
- PSPBSHYBJYTJCC-UHFFFAOYSA-N 9-ethyl-N-[(2-fluorophenyl)methyl]pyrido[3,4-b]indole-7-carboxamide Chemical compound C(C)N1C2=C(C3=CC=C(C=C13)C(=O)NCC1=C(C=CC=C1)F)C=CN=C2 PSPBSHYBJYTJCC-UHFFFAOYSA-N 0.000 claims 1
- JHLOSJVJHPLCQJ-UHFFFAOYSA-N 9-ethyl-N-[(3-methoxyphenyl)methyl]pyrido[3,4-b]indole-7-carboxamide Chemical compound C(C)N1C2=C(C3=CC=C(C=C13)C(=O)NCC1=CC(=CC=C1)OC)C=CN=C2 JHLOSJVJHPLCQJ-UHFFFAOYSA-N 0.000 claims 1
- DEHSXMGTTWQYHV-CQSZACIVSA-N 9-methyl-N-[(1R)-1-phenylethyl]pyrido[3,4-b]indole-7-carboxamide Chemical compound CN1C2=C(C3=CC=C(C=C13)C(=O)N[C@H](C)C1=CC=CC=C1)C=CN=C2 DEHSXMGTTWQYHV-CQSZACIVSA-N 0.000 claims 1
- KSMHODYMLODQNZ-UHFFFAOYSA-N 9-methyl-N-[[3-(trifluoromethoxy)phenyl]methyl]pyrido[3,4-b]indole-7-carboxamide Chemical compound CN1C2=C(C3=CC=C(C=C13)C(=O)NCC1=CC(=CC=C1)OC(F)(F)F)C=CN=C2 KSMHODYMLODQNZ-UHFFFAOYSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- ZUPXTGFATWSXGC-CYBMUJFWSA-N C1(=CC=CC=C1)[C@@H](C)NC(=O)C1=CC=C2C3=C(NC2=C1)C=NC=C3 Chemical compound C1(=CC=CC=C1)[C@@H](C)NC(=O)C1=CC=C2C3=C(NC2=C1)C=NC=C3 ZUPXTGFATWSXGC-CYBMUJFWSA-N 0.000 claims 1
- FPPPDEGTHKDSLM-UHFFFAOYSA-N COC=1C=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)C)C=CC1 Chemical compound COC=1C=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)C)C=CC1 FPPPDEGTHKDSLM-UHFFFAOYSA-N 0.000 claims 1
- XKIGTHQQQJJAJT-CYBMUJFWSA-N COc1cccc(c1)[C@@H](C)NC(=O)c1ccc2c(c1)[nH]c1c(C)nccc21 Chemical compound COc1cccc(c1)[C@@H](C)NC(=O)c1ccc2c(c1)[nH]c1c(C)nccc21 XKIGTHQQQJJAJT-CYBMUJFWSA-N 0.000 claims 1
- CUCWGQZKQLQPTA-CQSZACIVSA-N COc1cccc(c1)[C@@H](C)NC(=O)c1ccc2c(c1)[nH]c1cnc(C)cc21 Chemical compound COc1cccc(c1)[C@@H](C)NC(=O)c1ccc2c(c1)[nH]c1cnc(C)cc21 CUCWGQZKQLQPTA-CQSZACIVSA-N 0.000 claims 1
- OPVSJIZFISHPHE-OAHLLOKOSA-N C[C@@H](NC(=O)c1ccc2c(c1)n(CC#N)c1cnccc21)c1ccccc1 Chemical compound C[C@@H](NC(=O)c1ccc2c(c1)n(CC#N)c1cnccc21)c1ccccc1 OPVSJIZFISHPHE-OAHLLOKOSA-N 0.000 claims 1
- PVXGUMORIMJFSS-GOSISDBHSA-N C[C@@H](NC(=O)c1ccc2c(c1)n(CCN1CCCC1)c(=O)c1cnccc21)c1ccc(F)cc1 Chemical compound C[C@@H](NC(=O)c1ccc2c(c1)n(CCN1CCCC1)c(=O)c1cnccc21)c1ccc(F)cc1 PVXGUMORIMJFSS-GOSISDBHSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- QKQXIEVXAPHKLX-UHFFFAOYSA-N ClC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)C)C=CC=C1 Chemical compound ClC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)C)C=CC=C1 QKQXIEVXAPHKLX-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000003890 Coronary Vasospasm Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- VVPBUFWVNIAUKT-UHFFFAOYSA-N FC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)C)C=C(C=C1)OC Chemical compound FC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)C)C=C(C=C1)OC VVPBUFWVNIAUKT-UHFFFAOYSA-N 0.000 claims 1
- BMEMOHHPYXVQJC-CQSZACIVSA-N FC1=CC=C(C=C1)[C@@H](C)NC(=O)C=1C=CC2=C(N(C(C3=CN=CC=C23)=O)CCO)C=1 Chemical compound FC1=CC=C(C=C1)[C@@H](C)NC(=O)C=1C=CC2=C(N(C(C3=CN=CC=C23)=O)CCO)C=1 BMEMOHHPYXVQJC-CQSZACIVSA-N 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- JVKHVHALWMOQBH-UHFFFAOYSA-N N-(2-hydroxy-1-phenylethyl)-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound OCC(C1=CC=CC=C1)NC(=O)C1=CC=C2C3=C(NC2=C1)C=NC=C3 JVKHVHALWMOQBH-UHFFFAOYSA-N 0.000 claims 1
- RHMGKHDUBRRMSS-UHFFFAOYSA-N N-(2-hydroxy-1-phenylethyl)-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)NC(CO)C1=CC=CC=C1 RHMGKHDUBRRMSS-UHFFFAOYSA-N 0.000 claims 1
- LKMNKIPZENZTEM-CYBMUJFWSA-N N-[(1R)-1-(3-methoxyphenyl)ethyl]-6-oxo-5H-benzo[c][1,7]naphthyridine-8-carboxamide Chemical compound COC=1C=C(C=CC=1)[C@@H](C)NC(=O)C=1C=CC2=C(C(NC3=CN=CC=C23)=O)C=1 LKMNKIPZENZTEM-CYBMUJFWSA-N 0.000 claims 1
- UYWYQQVLMBMSSZ-CQSZACIVSA-N N-[(1R)-1-(3-methoxyphenyl)ethyl]-9-methylpyrido[3,4-b]indole-7-carboxamide Chemical compound COC=1C=C(C=CC=1)[C@@H](C)NC(=O)C1=CC=C2C3=C(N(C2=C1)C)C=NC=C3 UYWYQQVLMBMSSZ-CQSZACIVSA-N 0.000 claims 1
- LCXPFCGRIBLRQH-CYBMUJFWSA-N N-[(1R)-1-(3-methoxyphenyl)ethyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound COC=1C=C(C=CC=1)[C@@H](C)NC(=O)C1=CC=C2C3=C(NC2=C1)C=NC=C3 LCXPFCGRIBLRQH-CYBMUJFWSA-N 0.000 claims 1
- QXAFXQGFQUHTBG-GFCCVEGCSA-N N-[(1R)-1-(4-fluorophenyl)ethyl]-5-oxo-6H-benzo[c][2,7]naphthyridine-8-carboxamide Chemical compound FC1=CC=C(C=C1)[C@@H](C)NC(=O)C=1C=CC2=C(NC(C3=CN=CC=C23)=O)C=1 QXAFXQGFQUHTBG-GFCCVEGCSA-N 0.000 claims 1
- JTLNDLQAESIMRK-CQSZACIVSA-N N-[(1R)-1-phenylethyl]-9-(2,2,2-trifluoroethyl)pyrido[3,4-b]indole-7-carboxamide Chemical compound C1(=CC=CC=C1)[C@@H](C)NC(=O)C1=CC=C2C3=C(N(C2=C1)CC(F)(F)F)C=NC=C3 JTLNDLQAESIMRK-CQSZACIVSA-N 0.000 claims 1
- QNJJZWIGOIKFRY-CYBMUJFWSA-N N-[(1R)-1-phenylethyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)N[C@H](C)C1=CC=CC=C1 QNJJZWIGOIKFRY-CYBMUJFWSA-N 0.000 claims 1
- KJFCGGMTRBKRMH-UHFFFAOYSA-N N-[(2,6-difluorophenyl)methyl]-1-fluoro-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)F)C(=CC=C1)F KJFCGGMTRBKRMH-UHFFFAOYSA-N 0.000 claims 1
- JLSVVFMGBNWRIK-UHFFFAOYSA-N N-[(2,6-difluorophenyl)methyl]-4-fluoro-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C=NC=C4F)C(=CC=C1)F JLSVVFMGBNWRIK-UHFFFAOYSA-N 0.000 claims 1
- UDUCDCJFGOIPOU-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-1-fluoro-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound ClC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)F)C=CC=C1 UDUCDCJFGOIPOU-UHFFFAOYSA-N 0.000 claims 1
- XYVOWWDUJUXOBT-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-5-methyl-6-oxobenzo[c][1,7]naphthyridine-8-carboxamide Chemical compound ClC1=C(C=CC=C1)CNC(=O)C=1C=CC2=C(C(N(C3=CN=CC=C23)C)=O)C=1 XYVOWWDUJUXOBT-UHFFFAOYSA-N 0.000 claims 1
- ZPXFEZKPKQJGEH-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-6-oxo-5H-benzo[c][1,7]naphthyridine-8-carboxamide Chemical compound ClC1=C(C=CC=C1)CNC(=O)C=1C=CC2=C(C(NC3=CN=CC=C23)=O)C=1 ZPXFEZKPKQJGEH-UHFFFAOYSA-N 0.000 claims 1
- PBOJPNFHHZYQAP-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-9-(2,2,2-trifluoroethyl)pyrido[3,4-b]indole-7-carboxamide Chemical compound ClC1=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)CC(F)(F)F)C=NC=C4)C=CC=C1 PBOJPNFHHZYQAP-UHFFFAOYSA-N 0.000 claims 1
- AHKAQEGHWJZFSR-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-9-(cyclopropylmethyl)pyrido[3,4-b]indole-7-carboxamide Chemical compound ClC1=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)CC2CC2)C=NC=C4)C=CC=C1 AHKAQEGHWJZFSR-UHFFFAOYSA-N 0.000 claims 1
- QENFYLVCIRIVKM-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-9-methylpyrido[3,4-b]indole-7-carboxamide Chemical compound ClC1=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)C)C=NC=C4)C=CC=C1 QENFYLVCIRIVKM-UHFFFAOYSA-N 0.000 claims 1
- NYISGPKKANKSQE-UHFFFAOYSA-N N-[(2-chlorophenyl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)NCC1=C(C=CC=C1)Cl NYISGPKKANKSQE-UHFFFAOYSA-N 0.000 claims 1
- ZEJOLYZNAVDDNW-UHFFFAOYSA-N N-[(2-fluoro-5-methoxyphenyl)methyl]-4-methyl-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound FC1=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C=NC=C4C)C=C(C=C1)OC ZEJOLYZNAVDDNW-UHFFFAOYSA-N 0.000 claims 1
- ZUOQOICMRPWBMS-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-9-ethylpyrido[3,4-b]indole-7-carboxamide Chemical compound ClC=1C=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)CC)C=NC=C4)C=CC=1 ZUOQOICMRPWBMS-UHFFFAOYSA-N 0.000 claims 1
- UFRRATJYGXSMBK-UHFFFAOYSA-N N-[(3-cyanophenyl)methyl]-1-fluoro-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound C(#N)C=1C=C(CNC(=O)C2=CC=C3C4=C(NC3=C2)C(=NC=C4)F)C=CC=1 UFRRATJYGXSMBK-UHFFFAOYSA-N 0.000 claims 1
- QUJFWDQLDROPNQ-UHFFFAOYSA-N N-[(3-cyanophenyl)methyl]-9-ethylpyrido[3,4-b]indole-7-carboxamide Chemical compound C(#N)C=1C=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)CC)C=NC=C4)C=CC=1 QUJFWDQLDROPNQ-UHFFFAOYSA-N 0.000 claims 1
- PKCXHBALRNOSON-UHFFFAOYSA-N N-[(3-cyanophenyl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)NCC1=CC(=CC=C1)C#N PKCXHBALRNOSON-UHFFFAOYSA-N 0.000 claims 1
- NOZJEXSKUJQOJK-UHFFFAOYSA-N N-[(3-fluorophenyl)methyl]-9-methylpyrido[3,4-b]indole-7-carboxamide Chemical compound FC=1C=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)C)C=NC=C4)C=CC=1 NOZJEXSKUJQOJK-UHFFFAOYSA-N 0.000 claims 1
- XVYKJEITTUFMBX-UHFFFAOYSA-N N-[(3-fluorophenyl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)NCC1=CC(=CC=C1)F XVYKJEITTUFMBX-UHFFFAOYSA-N 0.000 claims 1
- UEPUUKCJNKKKIG-UHFFFAOYSA-N N-[(3-methoxyphenyl)methyl]-6-oxo-5H-benzo[c][1,7]naphthyridine-8-carboxamide Chemical compound COC=1C=C(C=CC=1)CNC(=O)C=1C=CC2=C(C(NC3=CN=CC=C23)=O)C=1 UEPUUKCJNKKKIG-UHFFFAOYSA-N 0.000 claims 1
- OCYXEDHHDAFAOD-UHFFFAOYSA-N N-[(3-methoxyphenyl)methyl]-9-(2,2,2-trifluoroethyl)pyrido[3,4-b]indole-7-carboxamide Chemical compound COC=1C=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)CC(F)(F)F)C=NC=C4)C=CC=1 OCYXEDHHDAFAOD-UHFFFAOYSA-N 0.000 claims 1
- JBQXPVABCNBIOX-UHFFFAOYSA-N N-[(3-methoxyphenyl)methyl]-9-methylpyrido[3,4-b]indole-7-carboxamide Chemical compound COC=1C=C(CNC(=O)C2=CC=C3C4=C(N(C3=C2)C)C=NC=C4)C=CC=1 JBQXPVABCNBIOX-UHFFFAOYSA-N 0.000 claims 1
- FDZZKXTZIQYWIP-UHFFFAOYSA-N N-[(3-methoxyphenyl)methyl]-9H-pyrido[3,4-b]indole-7-carboxamide Chemical compound COC=1C=C(C=CC=1)CNC(=O)C1=CC=C2C3=C(NC2=C1)C=NC=C3 FDZZKXTZIQYWIP-UHFFFAOYSA-N 0.000 claims 1
- KCUGZRCBRGRTBG-UHFFFAOYSA-N N-[(4-methoxyphenyl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=NC=CC2=C1OC1=C2C=CC(=C1)C(=O)NCC1=CC=C(C=C1)OC KCUGZRCBRGRTBG-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 201000011634 coronary artery vasospasm Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- IEVLLIQPIWQGSI-UHFFFAOYSA-N ethyl 3-(3-methoxyphenyl)-3-(9H-pyrido[3,4-b]indole-7-carbonylamino)propanoate Chemical compound COC=1C=C(C=CC=1)C(CC(=O)OCC)NC(=O)C1=CC=C2C3=C(NC2=C1)C=NC=C3 IEVLLIQPIWQGSI-UHFFFAOYSA-N 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- RWXQCIYEZNPOSV-CYBMUJFWSA-N n-[(1r)-1-(3-methoxyphenyl)ethyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound COC1=CC=CC([C@@H](C)NC(=O)C=2C=C3C(C4=CC=NC=C4O3)=CC=2)=C1 RWXQCIYEZNPOSV-CYBMUJFWSA-N 0.000 claims 1
- DLPZMGRIJBHVOO-UHFFFAOYSA-N n-[(2,2-difluoro-1,3-benzodioxol-5-yl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=C2OC3=CN=CC=C3C2=CC=C1C(=O)NCC1=CC=C2OC(F)(F)OC2=C1 DLPZMGRIJBHVOO-UHFFFAOYSA-N 0.000 claims 1
- FIGOFTYJWYUBNF-UHFFFAOYSA-N n-[(2-fluorophenyl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound FC1=CC=CC=C1CNC(=O)C1=CC=C2C3=CC=NC=C3OC2=C1 FIGOFTYJWYUBNF-UHFFFAOYSA-N 0.000 claims 1
- ZSVOKYSHRZNMQH-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CC=C2C3=CC=NC=C3OC2=C1 ZSVOKYSHRZNMQH-UHFFFAOYSA-N 0.000 claims 1
- IWGWFAUCXMIZGV-UHFFFAOYSA-N n-[3-hydroxy-1-(3-methoxyphenyl)propyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound COC1=CC=CC(C(CCO)NC(=O)C=2C=C3C(C4=CC=NC=C4O3)=CC=2)=C1 IWGWFAUCXMIZGV-UHFFFAOYSA-N 0.000 claims 1
- ZAPFZTXQSCYRLE-UHFFFAOYSA-N n-[[3-(methanesulfonamido)phenyl]methyl]-[1]benzofuro[2,3-c]pyridine-7-carboxamide Chemical compound CS(=O)(=O)NC1=CC=CC(CNC(=O)C=2C=C3C(C4=CC=NC=C4O3)=CC=2)=C1 ZAPFZTXQSCYRLE-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 abstract description 4
- 125000000304 alkynyl group Chemical group 0.000 abstract description 4
- 125000004452 carbocyclyl group Chemical group 0.000 abstract description 2
- 101100148545 Caenorhabditis elegans snr-5 gene Proteins 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 260
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 14
- 239000012453 solvate Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-LNLMKGTHSA-N 1,1,2,2-tetradeuterioethanol Chemical compound [2H]C([2H])C([2H])([2H])O LFQSCWFLJHTTHZ-LNLMKGTHSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 101001053401 Arabidopsis thaliana Acid beta-fructofuranosidase 3, vacuolar Proteins 0.000 description 1
- 101001053395 Arabidopsis thaliana Acid beta-fructofuranosidase 4, vacuolar Proteins 0.000 description 1
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 1
- 101100459319 Arabidopsis thaliana VIII-2 gene Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361842098P | 2013-07-02 | 2013-07-02 | |
| US201361842098P | 2013-07-02 | ||
| PCT/US2014/044988 WO2015002915A1 (en) | 2013-07-02 | 2014-07-01 | Tricyclic pyri do-carboxam i d e derivatives as rock inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2633987T3 true ES2633987T3 (es) | 2017-09-26 |
Family
ID=51211901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14741757.0T Active ES2633987T3 (es) | 2013-07-02 | 2014-07-01 | Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9914740B2 (Direct) |
| EP (1) | EP3016951B1 (Direct) |
| JP (1) | JP6434968B2 (Direct) |
| CN (1) | CN105492444B (Direct) |
| AR (1) | AR096788A1 (Direct) |
| ES (1) | ES2633987T3 (Direct) |
| TW (1) | TW201506024A (Direct) |
| WO (1) | WO2015002915A1 (Direct) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9708337B2 (en) | 2013-02-22 | 2017-07-18 | Bristol-Myers Squibb Company | Aryl amide-based kinase inhibitors |
| WO2014134391A1 (en) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
| EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
| ES2634628T3 (es) | 2013-07-02 | 2017-09-28 | Bristol-Myers Squibb Company | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK |
| WO2015054358A1 (en) | 2013-10-11 | 2015-04-16 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US9902702B2 (en) | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
| JP6779214B2 (ja) | 2015-01-09 | 2020-11-04 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての環状ウレア |
| EP3268360B1 (en) | 2015-03-09 | 2019-04-24 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| EP3292124B1 (en) | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
| WO2016198691A1 (en) | 2015-06-11 | 2016-12-15 | Basilea Pharmaceutica Ag | Efflux-pump inhibitors and therapeutic uses thereof |
| WO2017033019A1 (en) * | 2015-08-26 | 2017-03-02 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) | Condensed tricyclic compounds as protein kinase inhibitors |
| UY37073A (es) | 2016-01-13 | 2017-07-31 | Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock, y las composiciones que los contienen |
| EP3426674A4 (en) | 2016-03-09 | 2019-08-14 | Blade Therapeutics, Inc. | CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| ES2781309T3 (es) | 2016-05-27 | 2020-09-01 | Bristol Myers Squibb Co | Triazolonas y tetrazolonas como inhibidores de ROCK |
| EP3481835A4 (en) | 2016-07-05 | 2020-02-26 | Blade Therapeutics, Inc. | CALPAIN MODULATORS AND THERAPEUTIC USE THEREOF |
| KR102491994B1 (ko) | 2016-07-07 | 2023-01-25 | 브리스톨-마이어스 스큅 컴퍼니 | Rock의 억제제로서의 스피로락탐 |
| EP3481828B1 (en) | 2016-07-07 | 2020-09-16 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
| WO2018009622A1 (en) | 2016-07-07 | 2018-01-11 | Bristol-Myers Squibb Company | Lactam, cyclic urea and carbamate, and triazolone derivatives as potent and selective rock inhibitors |
| SG10201912574WA (en) | 2016-09-28 | 2020-02-27 | Blade Therapeutics Inc | Calpain modulators and therapeutic uses thereof |
| ES2829400T3 (es) * | 2016-11-30 | 2021-05-31 | Bristol Myers Squibb Co | Inhibidores tricíclicos de Rho cinasa |
| WO2018228452A1 (zh) * | 2017-06-16 | 2018-12-20 | 成都先导药物开发有限公司 | 一种抑制 rock 的化合物及其用途 |
| KR102644889B1 (ko) | 2017-07-12 | 2024-03-06 | 브리스톨-마이어스 스큅 컴퍼니 | Rock 억제제로서의 스피로헵타닐 히단토인 |
| US12060341B2 (en) | 2017-07-12 | 2024-08-13 | Bristol-Myers Squibb Company | Spiroheptanyl hydantoins as ROCK inhibitors |
| EP3652165B1 (en) | 2017-07-12 | 2021-08-25 | Bristol-Myers Squibb Company | Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure |
| TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
| EP3652164B1 (en) | 2017-07-12 | 2023-06-21 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
| WO2019089868A1 (en) | 2017-11-03 | 2019-05-09 | Bristol-Myers Squibb Company | Diazaspiro rock inhibitors |
| JP2021523092A (ja) | 2018-03-21 | 2021-09-02 | ピラマル・ファーマ・リミテッドＰｉｒａｍａｌ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | アルファ−（ジアリールメチル）アルキルアミンの改良された不斉合成 |
| CN108299429B (zh) * | 2018-04-09 | 2021-10-08 | 中南大学 | 一类八氢苯并萘啶化合物及其制备方法和应用 |
| CN110283119A (zh) * | 2018-04-20 | 2019-09-27 | 长沙理工大学 | 一种合成全碳基取代吡啶衍生物的方法 |
| CN110759923B (zh) * | 2018-07-26 | 2022-08-30 | 上海医药工业研究院有限公司 | 嘧啶并吡咯并哒嗪衍生物、其中间体、制备方法、药物组合物和用途 |
| US20230148184A1 (en) * | 2020-02-28 | 2023-05-11 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2021238965A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
| CN112010853A (zh) * | 2020-09-01 | 2020-12-01 | 成都大学 | 一种食品中杂环胺风险物质norharman及类似物的合成方法 |
| IL301964A (en) | 2020-10-08 | 2023-06-01 | Redona Therapeutics Inc | History of benzo[H]quinazoline-4-amine and thiano[2,3-H]quinazoline-4-amine for cancer treatment |
| EP4395889A1 (en) * | 2021-08-30 | 2024-07-10 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250000083A1 (en) | 2021-11-11 | 2025-01-02 | The Doshisha | Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation |
| CN114544851B (zh) * | 2022-02-22 | 2023-12-15 | 苏州正济医药研究有限公司 | 一种测定邻氯苯甘氨酸甲酯酒石酸盐及杂质的分析方法 |
| CN117105779A (zh) * | 2023-07-18 | 2023-11-24 | 河南师范大学 | 一种5-溴-2-甲酰基苯甲酸甲酯的制备方法 |
| CN117263934A (zh) * | 2023-08-16 | 2023-12-22 | 上海凌凯医药科技有限公司 | 一种5H-苯并[c][1,6]萘啶-6-酮类衍生物的制备方法 |
| CN119874716B (zh) * | 2025-03-27 | 2025-07-15 | 上海隆盛化工有限公司 | 1-氯-6,8-二氟-7-异丙基苯并呋喃并[2,3-c]吡啶及其合成方法和应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU168776B (Direct) | 1973-11-09 | 1976-07-28 | ||
| HU168036B (Direct) | 1973-11-09 | 1976-02-28 | ||
| CA1098910A (en) | 1978-06-15 | 1981-04-07 | Robert N. Schut | 3-amino-2-(5-fluoro and 5-methoxy-1h-indol-3-yl) propanoic acid derivatives |
| JPS57116067A (en) | 1981-01-12 | 1982-07-19 | Sankyo Kagaku Kk | Novel 8-quinolinesulfonyl derivative, its synthesis and use |
| DE3703435A1 (de) | 1987-02-05 | 1988-08-18 | Thomae Gmbh Dr K | Neue thiazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| IE68593B1 (en) | 1989-12-06 | 1996-06-26 | Sanofi Sa | Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them |
| US5945380A (en) | 1995-05-26 | 1999-08-31 | Bayer Aktiengesellschaft | Pyridyl-thiazoles and their use to protect plants against infections by micro-organisms |
| ES2196396T3 (es) | 1996-12-23 | 2003-12-16 | Bristol Myers Squibb Pharma Co | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| ATE257703T1 (de) | 1997-10-27 | 2004-01-15 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| WO1999052906A1 (de) | 1998-04-08 | 1999-10-21 | Bayer Aktiengesellschaft | Substituierte oxazolyl- und thiazolyl-uracil herbizide |
| CA2380206A1 (en) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
| MEP28108A (en) * | 2000-03-15 | 2010-10-10 | Sanofi Aventis Deutschland | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| WO2001068648A1 (en) | 2000-03-15 | 2001-09-20 | Aventis Pharma Deutschland Gmbh | Substituted beta-carbolines with ikb-kinase inhibiting activity |
| GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| EP1310494B1 (en) | 2000-08-11 | 2012-01-25 | Nippon Chemiphar Co., Ltd. | PPAR (delta) ACTIVATORS |
| JP2002053566A (ja) | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| US20020177594A1 (en) | 2001-03-14 | 2002-11-28 | Curtin Michael L. | Inhibitors of histone deacetylase |
| EP1371650A4 (en) | 2001-03-23 | 2005-05-04 | Nippon Chemiphar Co | ACTIVATED RECEPTOR ACTIVATOR BY PEROXYSOME PROLIFIERS |
| CA2665516A1 (en) | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
| EP1402900A1 (en) | 2001-06-11 | 2004-03-31 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| GB0123589D0 (en) | 2001-10-01 | 2001-11-21 | Syngenta Participations Ag | Organic compounds |
| US7163952B2 (en) | 2001-12-03 | 2007-01-16 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
| US7638536B2 (en) | 2002-01-18 | 2009-12-29 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
| CA2474322A1 (en) | 2002-01-25 | 2003-07-31 | Kylix Pharmaceuticals B.V. | 4(hetero-) aryl substituted (thia-/oxa-/pyra) zoles for inhibition of tie-2 |
| JP2005529923A (ja) | 2002-05-13 | 2005-10-06 | イーライ・リリー・アンド・カンパニー | 肥満および糖尿病の治療におけるメラニン凝集ホルモンアンタゴニストとして使用するための多環式化合物 |
| WO2004009017A2 (en) | 2002-07-18 | 2004-01-29 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| TW200424183A (en) | 2002-08-09 | 2004-11-16 | Nps Pharma Inc | New compounds |
| AU2003265395A1 (en) | 2002-08-14 | 2004-03-03 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| JP2006514684A (ja) | 2002-10-30 | 2006-05-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 |
| GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302672D0 (en) | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| WO2004071509A1 (ja) | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | オリゴデンドロサイト分化促進剤 |
| PL1611088T3 (pl) | 2003-04-07 | 2009-11-30 | Pharmacyclics Inc | Hydroksamiany jako środki terapeutyczne |
| JP2006523710A (ja) | 2003-04-16 | 2006-10-19 | メモリー・ファーマシューティカルズ・コーポレイション | ホスホジエステラーゼ４インヒビター |
| CN100545161C (zh) | 2003-08-15 | 2009-09-30 | 中国科学院上海药物研究所 | 一类杂环衍生物、制备方法及其用途 |
| US7351727B2 (en) | 2003-09-02 | 2008-04-01 | Bristol-Myers Squibb Company | Inhibitors of 15-lipoxygenase |
| MXPA06002567A (es) | 2003-09-06 | 2006-09-04 | Vertex Pharma | Moduladores de transportadores con casete de union de atp. |
| SA04250288B1 (ar) | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
| MXPA06004657A (es) | 2003-10-28 | 2006-06-27 | Pharmacia Corp | Combinaciones que comprenden un inhibidor de hsp90 y un inhibidor de fosfodiesterasa para tratar o prevenir la neoplasia. |
| WO2005044194A2 (en) | 2003-10-28 | 2005-05-19 | Pharmacia Corporation | TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR |
| WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| EP1713775A4 (en) | 2004-01-30 | 2009-08-12 | Smithkline Beecham Corp | CHEMICAL COMPOUNDS |
| WO2005077345A1 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077900A1 (ja) | 2004-02-18 | 2005-08-25 | Kyorin Pharmaceutical Co., Ltd. | ビシクロアミド誘導体 |
| MY148488A (en) | 2004-02-18 | 2013-04-30 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US7259155B2 (en) | 2004-05-05 | 2007-08-21 | Otsuka Pharmaceutical Factory, Inc. | Phosphonic diester derivatives |
| TW200637559A (en) | 2005-03-29 | 2006-11-01 | Shionogi & Co | 3-propenylcefem derivative |
| FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
| SG159561A1 (en) | 2005-05-09 | 2010-03-30 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| US7655446B2 (en) | 2005-06-28 | 2010-02-02 | Vertex Pharmaceuticals Incorporated | Crystal structure of Rho-kinase I kinase domain complexes and binding pockets thereof |
| BRPI0615524A2 (pt) * | 2005-07-11 | 2010-04-06 | Devgen Nv | derivados da amida como inibidores da quinase |
| WO2007062222A2 (en) | 2005-11-22 | 2007-05-31 | University Of South Florida | Inhibition of cell proliferation |
| WO2007075896A2 (en) | 2005-12-22 | 2007-07-05 | Kemia, Inc. | Heterocyclic cytokine inhibitors |
| TWI444370B (zh) | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
| WO2007116106A1 (es) | 2006-04-12 | 2007-10-18 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina |
| RU2008148962A (ru) | 2006-05-12 | 2010-06-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Избирательно действующие ингибиторы rоск протеинкиназы и их применение |
| JP5448164B2 (ja) | 2006-07-28 | 2014-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を変調する化合物 |
| JP5030114B2 (ja) | 2006-09-25 | 2012-09-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体をモジュレートする化合物 |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| WO2008124000A2 (en) | 2007-04-02 | 2008-10-16 | Ligand Pharmaceuticals Incorporated | Thiazole derivatives as androgen receptor modulator compounds |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| CN101801362B (zh) | 2007-06-22 | 2014-01-22 | 海德拉生物科学公司 | 用于治疗病症的方法和组合物 |
| CA2697382A1 (en) | 2007-08-27 | 2009-03-05 | Abbott Gmbh & Co. Kg | 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| ES2331220B1 (es) | 2007-10-02 | 2010-09-23 | Palobiofarma, S.L. | Nuevos compuestos como antagonistas de los receptores a1 de adenosina. |
| CA2699631A1 (en) | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Pyridazinone compounds and p2x7 receptor inhibitors |
| JP5492092B2 (ja) | 2007-11-07 | 2014-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| WO2009067607A2 (en) | 2007-11-20 | 2009-05-28 | Memory Pharmaceuticals Corporation | Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| WO2009081222A1 (en) | 2007-12-21 | 2009-07-02 | Glenmark Pharmaceuticals, S.A. | Substituted tricyclic pyridine or pyrimidine vanilloid receptor ligands |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| EP2251001A4 (en) | 2008-02-08 | 2013-01-09 | Shiseido Co Ltd | SKIN BLEACHING AND EXTERNAL PREPARATION FOR THE SKIN |
| WO2009114552A1 (en) | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| WO2009140519A1 (en) | 2008-05-14 | 2009-11-19 | Hydra Biosciences, Inc. | Compounds and compositions for treating chemical warfare agent-induced injuries |
| WO2010028193A1 (en) | 2008-09-03 | 2010-03-11 | Repligen Corporation | Compounds including pimelic acid derivatives as hdac inhibitors |
| US20100063085A1 (en) * | 2008-09-11 | 2010-03-11 | University Court Of The University Of Dundee | Method of treating learning impairment in down's syndrome subjects |
| WO2010029300A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Bis aromatic compounds for use in the treatment of inflammation |
| WO2010036821A1 (en) | 2008-09-24 | 2010-04-01 | Hydra Biosciences, Inc. | Methods and compositions for treating respiratory disorders |
| PL2379537T3 (pl) | 2008-12-19 | 2013-03-29 | Elanco Tiergesundheit Ag | Pochodne izooksazoliny i ich zastosowanie jako pestycydów |
| CN102325752B (zh) * | 2008-12-19 | 2015-02-04 | 百时美施贵宝公司 | 咔唑和咔啉激酶抑制剂 |
| WO2010075376A2 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| JP2012051804A (ja) * | 2008-12-26 | 2012-03-15 | Kyoto Univ | Ｅｇ５阻害剤 |
| UA103918C2 (en) | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8362249B2 (en) | 2009-04-27 | 2013-01-29 | Boehringer Ingelheim International Gmbh | CXCR3 receptor antagonists |
| AU2010258974A1 (en) | 2009-06-09 | 2012-01-12 | California Capital Equity, Llc | Pyridil-triazine inhibitors of hedgehog signaling |
| JP2013503174A (ja) | 2009-08-25 | 2013-01-31 | アブラクシス バイオサイエンス， エルエルシー | タキサンおよびヘッジホッグ阻害剤のナノ粒子組成物を使用する併用療法 |
| JP5856064B2 (ja) | 2009-11-17 | 2016-02-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物 |
| CA2783801A1 (en) | 2009-12-18 | 2011-06-23 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| JP5766690B2 (ja) | 2010-04-12 | 2015-08-19 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有するピリドン誘導体 |
| WO2011130740A2 (en) | 2010-04-16 | 2011-10-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use |
| US8685969B2 (en) * | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| US9000154B2 (en) | 2010-10-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
| DK2822555T3 (en) * | 2012-03-09 | 2018-02-05 | Lexicon Pharmaceuticals Inc | Inhibition of adapter-associated kinase 1 for the treatment of pain |
| US8703953B2 (en) | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| ES2634628T3 (es) | 2013-07-02 | 2017-09-28 | Bristol-Myers Squibb Company | Derivados tricíclicos de pirido-carboxamida como inhibidores ROCK |
| EP3016951B1 (en) | 2013-07-02 | 2017-05-31 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
-
2014
- 2014-07-01 EP EP14741757.0A patent/EP3016951B1/en not_active Not-in-force
- 2014-07-01 US US14/900,238 patent/US9914740B2/en active Active
- 2014-07-01 ES ES14741757.0T patent/ES2633987T3/es active Active
- 2014-07-01 JP JP2016524303A patent/JP6434968B2/ja not_active Expired - Fee Related
- 2014-07-01 TW TW103122739A patent/TW201506024A/zh unknown
- 2014-07-01 CN CN201480047827.6A patent/CN105492444B/zh not_active Expired - Fee Related
- 2014-07-01 WO PCT/US2014/044988 patent/WO2015002915A1/en not_active Ceased
- 2014-07-01 AR ARP140102466A patent/AR096788A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105492444B (zh) | 2018-09-07 |
| CN105492444A (zh) | 2016-04-13 |
| TW201506024A (zh) | 2015-02-16 |
| JP6434968B2 (ja) | 2018-12-05 |
| EP3016951B1 (en) | 2017-05-31 |
| AR096788A1 (es) | 2016-02-03 |
| EP3016951A1 (en) | 2016-05-11 |
| US9914740B2 (en) | 2018-03-13 |
| US20160152628A1 (en) | 2016-06-02 |
| WO2015002915A1 (en) | 2015-01-08 |
| JP2016523922A (ja) | 2016-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102785137B1 (ko) | Rip1 억제 화합물 및 그를 제조 및 사용하는 방법 | |
| US9914740B2 (en) | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | |
| CN112638917B (zh) | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| KR102913125B1 (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| US10781210B2 (en) | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | |
| JP6951406B2 (ja) | フラバグリン誘導体 | |
| US9725445B2 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| JP2000256358A (ja) | ピラゾール誘導体 | |
| JP2022530051A (ja) | 統合ストレス応答経路のモジュレーター | |
| JP2016523922A5 (Direct) | ||
| WO2019029620A1 (zh) | Atx抑制剂及其制备方法和应用 | |
| KR20180128015A (ko) | 피리미딘 및 그의 변이체, 및 그의 용도 | |
| KR20240115978A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| JP7301758B2 (ja) | 縮合二環式化合物、その組成物及び応用 | |
| JP2025087798A (ja) | コラーゲン１翻訳阻害剤およびその使用方法 | |
| US20240327408A1 (en) | Compounds containing tetrahydronaphthyridinone or tetrahydropyridopyrimidinone skeleton, preparation method therefor and pharmaceutical use thereof | |
| JP2020503334A (ja) | ピリミジン化合物 | |
| TWI902085B (zh) | 並環類衍生物、其製備方法、中間體和用途 | |
| CN108299436A (zh) | 黄嘌呤类化合物及其药物组合物和应用 | |
| JP6541777B2 (ja) | 神経変性障害およびアルツハイマー病の治療における使用ための二重阻害剤化合物 | |
| TW202613107A (zh) | 化合物及其用途 | |
| HK40088982A (zh) | Lpa受体拮抗剂及其用途 | |
| HK40088982B (zh) | Lpa受体拮抗剂及其用途 | |
| HK40068242A (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| HK40068242B (en) | Rip1 inhibitory compounds and methods for making and using the same |